查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425004

膀胱癌治疗和诊断市场，按诊断、癌症类型、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostic, By Cancer Type, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 289 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022 年膀胱癌治疗和诊断市场规模为 37.942 亿美元，2023 年至 2030 年复合CAGR为 5.7%。

膀胱癌治疗与诊断市场-市场动态

人们对膀胱疾病和可用疗法的认识不断提高、医疗保健支出不断增加以及膀胱癌负担的增加预计将推动市场需求

在人们对膀胱疾病和可用疗法的认识不断提高、医疗保健支出不断扩大以及膀胱癌负担日益加重等因素的推动下，膀胱癌治疗和诊断市场有望快速增长。例如，2022 年 3 月，世界膀胱癌患者联盟宣布了膀胱癌意识「不要变红」主题，以提高对警告信号和症状的认识，强调早期检测对于提高长期生存和品质的重要性的生活。此外，全球膀胱癌盛行率呈上升趋势，根据《2020年全球癌症观察站统计》，膀胱癌位居全球十大高发生癌症。同一份报告指出，2020年膀胱癌发生率已位居全球前10位。估计全球有 573,278 例膀胱癌新病例和 1,414,259 例前列腺癌新病例。全球癌症的高发生率是市场的重要驱动力。

膀胱癌治疗和诊断市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球膀胱癌治疗和诊断市场在预测期内（2023-2030）每年将以 5.7% 左右的CAGR增长

由于人们对膀胱疾病和可用疗法的认识不断提高、医疗保健支出不断扩大以及膀胱癌负担日益加重，膀胱癌治疗和诊断市场预计将以显着的速度增长

根据 Diagnostic，膀胱镜检查领域预计将在 2022 年显示最大的市场份额

根据癌症类型，移行细胞膀胱癌是 2022 年的主要细分市场

按地区划分，北美是 2022 年的主要收入来源

膀胱癌治疗与诊断市场細項分析：

全球膀胱癌治疗和诊断市场根据诊断、癌症类型和地区进行细分。

根据诊断，市场分为四个部分：膀胱镜检查、膀胱超音波、尿液分析、其他诊断。膀胱镜检查部门产生了最高的收入，预计在整个预测期内将保持领先。膀胱镜检查是一种使用插入尿道的专用内视镜观察膀胱和尿道内部的手术，预计将成为预测期内研究市场的主导部分。这种具有成本效益的方法是由越来越多的采用、膀胱癌盛行率的上升以及主要市场参与者推出的产品所推动的。

市场依癌症类型分为三个部分：移行细胞膀胱癌、鳞状细胞膀胱癌、其他癌症类型。预计到 2030 年，移行细胞膀胱癌细分市场将在全球膀胱癌诊断市场中占据重要份额，这主要是由于移行细胞膀胱癌的高发生率。

膀胱癌治疗与诊断市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲地区。这些区域根据开展业务的国家进一步划分。由于癌症盛行率上升，预计北美将在预测期内主导市场。例如，根据美国癌症协会2022年1月的估计，2022年美国将新增约81,180例膀胱癌病例，其中男性61,700例，女性19,480例。

膀胱癌治疗与诊断市场-竞争格局：

在膀胱癌治疗和诊断领域，各公司正在积极研究和开发创新方法。在治疗学中，一个值得注意的焦点是标靶治疗（特别是免疫疗法）的进步，以提高膀胱癌的治疗效果。免疫检查点抑制剂，例如帕博利珠单抗和阿替利珠单抗等药物，已获得针对特定膀胱癌类型的批准，并且正在进行的研究正在扩大治疗选择的范围。此外，该公司致力于探索有助于早期检测、预后和治疗反应评估的新型生物标记。这些生物标记可以帮助完善诊断方法并指导更个人化的治疗介入措施，从而有可能改善患者的治疗结果并减轻膀胱癌的整体负担。该领域的公司致力于全面解决与膀胱癌相关的挑战，从早期诊断到创新治疗方式，最终目标是提高患者护理和存活率。

最近的发展：

2022 年7 月，美国食品和癌症类型管理局(FDA) 同意审查ImmunityBio 的N-803 生物製品许可诊断(BLA)，这可能使患有或不患有Ta 或T1 疾病的非肌肉层浸润性膀胱癌症患者受益（NMIBC）原位癌（CIS）。

目录

第 1 章：膀胱癌治疗与诊断市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 膀胱癌治疗与诊断市场片段（按 Diagnostics）
    • 按癌症类型分類的膀胱癌治疗和诊断市场片段
    • 按国家/地区分類的膀胱癌治疗和诊断市场片段
    • 按地区分類的膀胱癌治疗和诊断市场片段
  • 竞争洞察

第 3 章：膀胱癌治疗和诊断主要市场趋势

  • 膀胱癌治疗与诊断市场驱动因素
    • 市场驱动因素的影响分析
  • 膀胱癌治疗与诊断市场限制
    • 市场限制影响分析
  • 膀胱癌治疗和诊断市场机会
  • 膀胱癌治疗与诊断市场未来趋势

第 4 章：膀胱癌治疗与诊断产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：膀胱癌治疗与诊断市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：膀胱癌治疗与诊断市场格局

  • 2022 年膀胱癌治疗与诊断市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：膀胱癌治疗与诊断市场 - 按诊断

  • 概述
    • 细分市场占有率分析（按诊断）
    • 膀胱镜检查
    • 膀胱超音波检查
    • 尿液分析
    • 其他诊断

第 8 章：膀胱癌治疗和诊断市场 - 按癌症类型

  • 概述
    • 按癌症类型分類的细分市场份额分析
    • 移行细胞膀胱癌
    • 鳞状细胞膀胱癌
    • 其他癌症类型

第 9 章：膀胱癌治疗和诊断市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美膀胱癌治疗和诊断主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（根据 Diagnostics）
    • 北美市场规模和预测（按癌症类型）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲膀胱癌治疗和诊断主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（根据 Diagnostics）
    • 欧洲市场规模和预测（按癌症类型）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区膀胱癌治疗和诊断主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太市场规模和预测（根据 Diagnostics）
    • 亚太地区市场规模和预测（按癌症类型）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲膀胱癌治疗和诊断主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模和预测（根据 Diagnostics）
    • 拉丁美洲市场规模与预测（按癌症类型）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲膀胱癌治疗和诊断主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（根据 Diagnostics）
    • 中东和非洲市场规模及预测（按癌症类型）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析 - 膀胱癌治疗与诊断产业

  • 竞争仪表板
  • 公司简介
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Lilly
    • F. Hoffmann-La Roche Ltd
    • GSK plc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Endo Pharmaceuticals Inc.
    • Johnson & Johnson Services

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2204

REPORT HIGHLIGHT

Bladder Cancer Therapeutics and Diagnostics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Bladder Cancer Therapeutics and Diagnostics Market- Market Dynamics

Increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer is expected to propel the market demand

The bladder cancer therapeutics and diagnostics market is poised for rapid growth, fueled by factors such as increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer. In March 2022, for example, the World Bladder Cancer Patient Coalition declared the 'Don't Go Red' theme for Bladder Cancer Awareness to raise awareness of warning signs and symptoms, underscoring the importance of early detection in enhancing long-term survival and quality of life. Furthermore, the global prevalence of bladder cancer is on the rise, with bladder cancer ranking among the top 10 high-incidence cancers worldwide according to the Global Cancer Observatory Statistics 2020. In the same report, it was noted that in 2020, there were an estimated 573,278 new cases of bladder cancer and 1,414,259 cases of prostate cancer worldwide. This high incidence of cancer globally is a significant driver for the market.

Bladder Cancer Therapeutics and Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global Bladder Cancer Therapeutics and Diagnostics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Bladder Cancer Therapeutics and Diagnostics Market is projected to grow at a significant rate driven by increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer

Based on Diagnostic, the Cystoscopy segment was predicted to show maximum market share in the year 2022

Based on Cancer Type, Transitional Cell Bladder Cancer was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Bladder Cancer Therapeutics and Diagnostics Market- Segmentation Analysis:

The Global Bladder Cancer Therapeutics and Diagnostics Market is segmented on the basis of Diagnostic, By Cancer Type, and Region.

Based on the Diagnostic, the market is divided into four segments: Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics. The Cystoscopy segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. Cystoscopy, a procedure for visualizing the interior of the bladder and urethra using a specialized endoscope inserted through the urethra, is projected to be the dominant segment in the studied market during the forecast period. This cost-effective method is driven by increasing adoption, the rising prevalence of bladder cancer, and product launches by key market players.

The market is categorized by Cancer Type into three segments: Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types. The transitional cell bladder cancer segment is expected to hold a significant share of the global bladder cancer diagnostics market by 2030, primarily due to the high incidence of transitional cell bladder cancer.

Bladder Cancer Therapeutics and Diagnostics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period owing to the rising prevalence of cancer. For instance, as to the January 2022 estimates from the American Cancer Society, about 81,180 new cases of bladder cancer would occur in the United States year 2022, with 61,700 cases in men and 19,480 cases in women.

Bladder Cancer Therapeutics and Diagnostics Market- Competitive Landscape:

In the realm of bladder cancer therapeutics and diagnostics, companies are fervently researching and developing innovative approaches. In therapeutics, a notable focus is on the advancement of targeted therapies, particularly immunotherapies, to enhance bladder cancer treatment outcomes. Immune checkpoint inhibitors, exemplified by drugs like pembrolizumab and atezolizumab, have secured approvals for specific bladder cancer types, and ongoing investigations are expanding the repertoire of treatment options. Moreover, companies are dedicated to exploring novel biomarkers that can aid in early detection, prognosis, and treatment response assessment. These biomarkers can help refine diagnostic methods and guide more personalized therapeutic interventions, potentially improving patient outcomes and reducing the overall burden of bladder cancer. Companies in this space are committed to addressing the challenges associated with bladder cancer comprehensively, from early diagnosis to innovative treatment modalities, with the ultimate goal of enhancing patient care and survival rates.

Recent Developments:

In July 2022, the United States Food and Cancer Type Administration (FDA) agreed to review ImmunityBio's Biologics License Diagnostic (BLA) for N-803, which could benefit patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET KEY PLAYERS

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Lilly
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Endo Pharmaceuticals Inc.
  • Johnson & Johnson Services

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTIC

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Other Diagnostics

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bladder Cancer Therapeutics and Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Diagnostics
    • 2.1.2. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Country
    • 2.1.4. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Bladder Cancer Therapeutics and Diagnostics Key Market Trends

  • 3.1. Bladder Cancer Therapeutics and Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bladder Cancer Therapeutics and Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bladder Cancer Therapeutics and Diagnostics Market Opportunities
  • 3.4. Bladder Cancer Therapeutics and Diagnostics Market Future Trends

4. Bladder Cancer Therapeutics and Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bladder Cancer Therapeutics and Diagnostics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bladder Cancer Therapeutics and Diagnostics Market Landscape

  • 6.1. Bladder Cancer Therapeutics and Diagnostics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bladder Cancer Therapeutics and Diagnostics Market - By Diagnostics

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnostics, 2022 & 2030 (%)
    • 7.1.2. Cystoscopy
    • 7.1.3. Bladder Ultrasound
    • 7.1.4. Urinalysis
    • 7.1.5. Other Diagnostics

8. Bladder Cancer Therapeutics and Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2022 & 2030 (%)
    • 8.1.2. Transitional Cell Bladder Cancer
    • 8.1.3. Squamous Cell Bladder Cancer
    • 8.1.4. Other Cancer Types

9. Bladder Cancer Therapeutics and Diagnostics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Bladder Cancer Therapeutics and Diagnostics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. AstraZeneca
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Lilly
    • 10.2.4. F. Hoffmann-La Roche Ltd
    • 10.2.5. GSK plc
    • 10.2.6. Novartis AG
    • 10.2.7. Pfizer Inc.
    • 10.2.8. Sanofi
    • 10.2.9. Endo Pharmaceuticals Inc.
    • 10.2.10. Johnson & Johnson Services

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Diagnostics Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Diagnostics
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics 2018-2030 (USD Million)
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Cancer Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Cancer Type
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type 2018-2030 (USD Million)
  • TABLE Bladder Cancer Therapeutics and Diagnostics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bladder Cancer Therapeutics and Diagnostics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE North America Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Europe Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Latin America Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Diagnostics, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market, by Cancer Type, 2018-2030 (USD Million)

List of Figures

  • FIGURE Bladder Cancer Therapeutics and Diagnostics Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Diagnostics segment market share analysis, 2022 & 2030
  • FIGURE Diagnostics segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Cancer Type segment market share analysis, 2022 & 2030
  • FIGURE Cancer Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Europe Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Latin America Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE Germany Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE India Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE Brazil Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market share analysis by country, 2022
  • FIGURE Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Bladder Cancer Therapeutics and Diagnostics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)